Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the long-term safety, efficacy, and pharmacokinetics of KPS-0373 in SCD patients.


Clinical Trial Description

n/a


Study Design

N/A


Related Conditions & MeSH terms


NCT number NCT01970111
Study type Interventional
Source Kissei Pharmaceutical Co., Ltd.
Contact
Status Completed
Phase Phase 3

See also
  Status Clinical Trial Phase
Completed NCT01970098 - A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Phase 3
Completed NCT02889302 - An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Phase 3
Completed NCT04107740 - C-Trelin Orally Disintegrated(OD) Tablet 5mg in Ataxia Due to Spinocerebellar Degeneration Phase 4
Completed NCT01004016 - A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Phase 2
Completed NCT01970137 - A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Phase 3
Completed NCT00863538 - Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Phase 2
Completed NCT01970124 - A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Phase 3